## Abstract ## Background and Objective Basal cell carcinomas (BCCs) have supporting vasculature that could serve as a target for 595βnm pulsed dye laser (PDL). The objective of this study was to determine the effect of repeated PDL treatments on BCCs of superficial and nodular subtypes and of var
The pulsed dye laser for the treatment of basal cell carcinoma
β Scribed by Christopher J. Ballard; Maria P. Rivas; Michael Patrick McLeod; Sonal Choudhary; George W. Elgart; Keyvan Nouri
- Publisher
- Springer-Verlag
- Year
- 2011
- Tongue
- English
- Weight
- 87 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0268-8921
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: Chronic radiodermatitis after radiotherapy for carcinoma of the breast is a common sequela of treatment and can be distressing for the patient. the skin is atrophic and shows prominent telangiectasia due to dilatation of a reduced or poorly supported skin vasculature. the pulsed dye
We report our initial experience using the pulsed dye laser in 26 patients with urolithiasis. The patients ranged in age from 27 to 82 years; 11 patients were female and 15 were male. Of the 26 patients, 4 stones were in the kidney, 21 were in the ureter, and one was in the bladder. Surgical time ra
## Background and objective: Sebaceous gland hyperplasia may be treated by cryotherapy, cauterization, topical chemicals, or excision. the major disadvantage of these therapeutic strategies is a considerable risk of postoperative scarring or dyspigmentation. the pulsed dye laser may be an effective
Lupus pernio, a form of cutaneous sarcoidosis usually affecting the face, is often disfiguring and resistant to therapies, both medical and surgical. To our knowledge, there have been no previous reports of laser therapy for this condition. We describe a case of nasal lupus pernio successfully manag
## Abstract ## Backgrounds and Objectives Photodynamic therapy (PDT), via topical aminolevulinic acid (ALA) is an effective treatment for basal cell carcinomas not exceeding a depth of 2 mm. This limits the treatment of basal cell carcinoma (nonβmelanoma skin cancer) to superficial forms and nodul